A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms SUNRISE
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Mar 2019 Planned End Date changed from 22 Apr 2022 to 13 May 2022.
- 26 Mar 2019 Planned primary completion date changed from 18 Jun 2021 to 9 Jul 2021.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.